NEXALIN abstracts accepted at 2026 NYC Neuromodulation Conference
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall Street rallies as AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- Wall Street rallies as AI optimism reignites and Treasury yields retreat
Nexalin Technology Announces Two Clinical Abstracts Accepted for Presentation at the 2026 NYC Neuromodulation Conference Highlighting Preliminary Clinical Results Across Anxiety, Depression, Insomnia
June 16, 2026 9:15 AM EDTAccepted abstracts showcase Nexalins proprietary DIFS 15 mA 77.5 Hz treatment platform and clinical improvements across anxiety, depression, insomnia and quality of life
Data to be presented include 77.8% anxiety response rate at end of treatment, durable benefits maintained at 8-week follow-up and no serious adverse events, seizures or manic/hypomanic switches reported
Presentations of clinical data further strengthen the scientific viability of Nexalins new proprietary non-invasive approach to deep-brain frequency-based neurostimulation as the Company prepares for global commercial initiatives
HOUSTON, TX, June 16, 2026 (GLOBE NEWSWIRE) -- Nexalin... More
